Coriell to Use Affy Chips in Large Genotyping Study of Disease Risk Factors
The Coriell Institute for Medical Research last week kicked off a study that plans to genotype up to 100,000 patients to determine genetic risk factors associated with cancer, heart and blood vessel diseases, lung disease, as well as stroke and other complex health conditions.
The study, called the Delaware Valley Personalized Medicine Project, will enroll 10,000 participants over the next three years from the Philadelphia metropolitan area with the goal of eventually reaching 100,000 patients. Other partners in the program, which will use Affymetrix’s Genome-Wide Human SNP Array 6.0 genotyping platform, include the Fox Chase Cancer Center, Cooper University Hospital, and Virtua Health.
The initiative has so far raised $5 million from the William G. Rohrer Foundation, the William T. Read Legacy Fund, Eleanor Read, the Daniel J. Ragone Family Foundation, and Coriell's endowment.
Under the project, participants will be encouraged to consult with their physicians about their risk variants “and to make important decisions about preventative care and proper medical treatments,” Coriell said.
All patients “will control access to their genetic profiles and will determine whether they wish the information to become part of their medical records in the future,” the institute added. There is no charge to participate.
Erin O'Shea, a professor of molecular biology at Harvard University, will chair the project’s Informed Cohort Oversight Board, which will determine which risk variants are “appropriate” for use by patients and physicians to improve health.
Alberta Transplant Genomics Center Using GenoLogics' Geneus Software
The University of Alberta has installed GenoLogics’ Geneus software in its Alberta Transplant Applied Genomics Center, the company said last week.
The center is using the informatics and scientific-management system in its diagnostic gene-expression and transcriptomics research with an eye toward developing molecular diagnostics for organ-transplant candidates.
The research uses gene-expression microarrays to understand the causes of organ rejection and has already led to a series of gene-expression sets that are useful in assessing rejection events, GenoLogics said.
The center also expects to use proteomics and metabolomics research to add to its ongoing efforts and to partner with pharmaceutical companies to develop drugs aimed at countering organ rejection.
Financial terms of the agreement were not released.
Clinical Data Consolidating Cogenics in NC, Texas; No Layoffs Expected
Clinical Data is in the process of separating its PGx Health and Cogenics businesses by consolidating Cogenics’ Morrisville, NC, and Houston, Texas operations, Stephen Sharp, Cogenics’ senior director of marketing, told BioArray News sister publication GenomeWeb News last week.
By the end of the year, Sharp said, Cogenics, which provides genomic services, will have removed its operations from New Haven, Conn., allowing the PGx Health business to use that facility for its diagnostics and therapeutics efforts.
Sharp said the company plans to expand its staff in both Morrisville and Houston, and he does not expect any layoffs associated with the restructuring.
He added that the Morrisville facility will focus on genotyping services and the Houston facility will focus on sequencing.